2. Search Result
Search Result
Results for "

hSGLT2,

" in MedChemExpress (MCE) Product Catalog:

13

Inhibitors & Agonists

1

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0143
    Phlorizin
    5+ Cited Publications

    Floridzin

    		 SGLT Na+/K+ ATPase Metabolic Disease
    Phlorizin (Floridzin) is a non-selective SGLT inhibitor with Kis of 300 and 39 nM for hSGLT1 and hSGLT2, respectively. Phlorizin is also a Na +/K +-ATPase inhibitor.
    Phlorizin
  • HY-10451
    Canagliflozin
    Maximum Cited Publications
    28 Publications Verification

    JNJ 28431754

    		 SGLT Metabolic Disease Cancer
    Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin
  • HY-I0383
    Canagliflozin hemihydrate
    Maximum Cited Publications
    28 Publications Verification

    JNJ 28431754 hemihydrate

    		 SGLT Metabolic Disease Cancer
    Canagliflozin hemihydrate (JNJ28431754 hemihydrate) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively .
    Canagliflozin hemihydrate
  • HY-137145
    galacto-Dapagliflozin

    		SGLT Others
    Galacto-dapagliflozin is a selective inhibitor for hSGLT2 with Ki of 25 nM .
    galacto-Dapagliflozin
  • HY-112807
    SGLT inhibitor-1

    		SGLT Metabolic Disease
    SGLT inhibitor-1 is a potent dual inhibitor of sodium glucose co-transporter proteins (SGLTs), inhibits hSGLT1 and hSGLT2 with IC50s of 43 nM and 9 nM, respectively .
    <em>SGLT</em> inhibitor-1
  • HY-14810
    Atigliflozin

    AVE-2268

    		 SGLT Metabolic Disease
    Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
    Atigliflozin
  • HY-15461
    Ertugliflozin
    1 Publications Verification

    PF-04971729

    		 SGLT Metabolic Disease
    Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
    Ertugliflozin
  • HY-114308
    SGL5213

    		SGLT Metabolic Disease
    SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment .
    SGL5213
  • HY-10451S2
    Canagliflozin-d6

    JNJ 28431754-d6

    		 SGLT
    Canagliflozin-d6 is the deuterium labeled Canagliflozin[1]. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively[2].
    Canagliflozin-d6
  • HY-15461A
    Ertugliflozin L-pyroglutamic acid
    1 Publications Verification

    PF-04971729 L-pyroglutamic acid

    		 SGLT Metabolic Disease
    Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
    Ertugliflozin L-pyroglutamic acid
  • HY-101122
    LX2761

    LX2761 is chemically stable and potent inhibitor against sodium-dependent glucose cotransporter 1 (SGLT1) and SGLT2 in vitro with IC50s of 2.2 nM and 2.7nM for hSGLT1 and hSGLT2, but displays specific SGLT1 inhibition in the gastrointestinal (GI) tract .
    LX2761
  • HY-15461S1
    Ertugliflozin-d9

    PF-04971729-d9

    		 SGLT Isotope-Labeled Compounds Metabolic Disease
    Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus [2].
    Ertugliflozin-d9
  • HY-14945
    Remogliflozin etabonate

    GSK189075

    		 SGLT Metabolic Disease
    Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
    Remogliflozin etabonate

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: